Oncothyreon reports promising lung cancer drug test
February 26th, 2008
Oncothyreon Inc. reported that a study of its PX-478 treatment for lung cancer in a test on mice “resulted in significant inhibition of tumor growth.”
The test on a model of lung cancer in mice, which the Bellevue biotech said closely mimics the disease in humans, was promising and the treatment “significantly improved survival,” the company said.